Amgen filed a Worker Adjustment and Retraining in California with plans to cut 172 jobs at the company’s headquarters and U.S. field operations effective December 31, 2019.
The state of California sued Juul Labs Inc., alleging the e-cigarette maker engaged in a “systematic” and “wildly successful” campaign to attract teenagers to the San Francisco company’s nicotine devices.
Three years after Novartis opened a $1 billion research & development facility in Shanghai, the company is shifting the focus of the site from drug discovery to commercial development.
An Oklahoma judge said Johnson & Johnson must pay that state $465 million for fueling the opioid epidemic through the deceptive marketing of painkillers, down from his original award of $572 million.
Novartis AG won U.S. approval for the company’s experimental sickle cell disease drug Adakveo.
Mylan has come under fire from the U.S. Food and Drug Administration over inadequate good manufacturing practices at one of the company’s drug manufacturing facilities in India.
Johnson & Johnson filed for an approval from European regulators for the company’s two-dose experimental vaccine to protect against Ebola.
China’s Bio-Thera Solutions Ltd. won a regulatory approval for the company’s version of AbbVie Inc.’s blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world’s second-largest drug market.
A team of Abbott scientists identified a new subtype of the human immunodeficiency virus, called HIV-1 Group M, subtype L.
AstraZeneca is significantly expanding the company’s footprint in China with the establishment of a global R&D center and launch of a $1 billion fund aimed at supporting that nation’s healthcare sector.